Ad is loading...
BEAM
Price
$24.05
Change
-$2.26 (-8.59%)
Updated
Nov 15 closing price
107 days until earnings call
EXAI
Price
$4.69
Change
-$0.62 (-11.68%)
Updated
Nov 15 closing price
One day until earnings call
Ad is loading...

BEAM vs EXAI

Header iconBEAM vs EXAI Comparison
Open Charts BEAM vs EXAIBanner chart's image
Beam Therapeutics
Price$24.05
Change-$2.26 (-8.59%)
Volume$2.26M
CapitalizationN/A
Exscientia
Price$4.69
Change-$0.62 (-11.68%)
Volume$2.01M
CapitalizationN/A
BEAM vs EXAI Comparison Chart
Loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
EXAI
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
BEAM vs. EXAI commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a StrongSell and EXAI is a Sell.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (BEAM: $24.05 vs. EXAI: $4.69)
Brand notoriety: BEAM and EXAI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 218% vs. EXAI: 294%
Market capitalization -- BEAM: $1.99B vs. EXAI: $613.55M
BEAM [@Biotechnology] is valued at $1.99B. EXAI’s [@Biotechnology] market capitalization is $613.55M. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 0 FA rating(s) are green whileEXAI’s FA Score has 0 green FA rating(s).

  • BEAM’s FA Score: 0 green, 5 red.
  • EXAI’s FA Score: 0 green, 5 red.
According to our system of comparison, both BEAM and EXAI are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 4 TA indicator(s) are bullish while EXAI’s TA Score has 4 bullish TA indicator(s).

  • BEAM’s TA Score: 4 bullish, 5 bearish.
  • EXAI’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, BEAM is a better buy in the short-term than EXAI.

Price Growth

BEAM (@Biotechnology) experienced а -11.12% price change this week, while EXAI (@Biotechnology) price change was -13.79% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

BEAM is expected to report earnings on Mar 04, 2025.

EXAI is expected to report earnings on Mar 20, 2025.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($1.99B) has a higher market cap than EXAI($614M). BEAM YTD gains are higher at: -11.646 vs. EXAI (-26.833). EXAI has higher annual earnings (EBITDA): -117.52M vs. BEAM (-162.88M). BEAM has more cash in the bank: 1.01B vs. EXAI (293M). EXAI has less debt than BEAM: EXAI (21.4M) vs BEAM (165M). BEAM has higher revenues than EXAI: BEAM (353M) vs EXAI (21M).
BEAMEXAIBEAM / EXAI
Capitalization1.99B614M324%
EBITDA-162.88M-117.52M139%
Gain YTD-11.646-26.83343%
P/E RatioN/AN/A-
Revenue353M21M1,681%
Total Cash1.01B293M344%
Total Debt165M21.4M771%
TECHNICAL ANALYSIS
Technical Analysis
BEAMEXAI
RSI
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
84%
Momentum
ODDS (%)
Bullish Trend 3 days ago
78%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
89%
Advances
ODDS (%)
Bullish Trend 7 days ago
81%
Bullish Trend 7 days ago
81%
Declines
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
N/A
Bullish Trend 3 days ago
81%
View a ticker or compare two or three
Ad is loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
EXAI
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GLIFX15.970.09
+0.57%
Lazard Global Listed Infrastructure Inst
WLCTX11.40-0.07
-0.61%
Wilshire International Equity Invmt
MWMIX36.05-0.68
-1.85%
VanEck Morningstar Wide Moat I
IHSUX28.67-0.61
-2.08%
Hartford Small Company R5
NQQQX41.07-1.01
-2.40%
Shelton Nasdaq-100 Index Institutional

BEAM and

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
-8.59%
CRSP - BEAM
74%
Closely correlated
+0.85%
NTLA - BEAM
69%
Closely correlated
-7.61%
DNLI - BEAM
65%
Loosely correlated
-11.95%
EDIT - BEAM
64%
Loosely correlated
-3.97%
RXRX - BEAM
62%
Loosely correlated
-10.64%
More

EXAI and

Correlation & Price change

A.I.dvisor indicates that over the last year, EXAI has been loosely correlated with RXRX. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if EXAI jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXAI
1D Price
Change %
EXAI100%
-11.68%
RXRX - EXAI
56%
Loosely correlated
-10.64%
BEAM - EXAI
48%
Loosely correlated
-8.59%
NTLA - EXAI
44%
Loosely correlated
-7.61%
CRSP - EXAI
43%
Loosely correlated
+0.85%
ABCL - EXAI
42%
Loosely correlated
-3.99%
More